ArticleBlood advances2021

Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.

Kishan K Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.